Fate Therapeutics Stock Buy Hold or Sell Recommendation
| FATE Stock | USD 5.04 0.23 4.36% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Fate Therapeutics is 'Strong Sell'. Macroaxis provides Fate Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding FATE positions. The advice algorithm takes into account all of Fate Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Fate Therapeutics' buy or sell advice are summarized below:
Real Value 4.83 | Target Price 7.28 | Hype Value 5.04 | Market Value 5.04 | Naive Value 4.7 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Fate Therapeutics given historical horizon and risk tolerance towards Fate Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Fate Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Fate |
Execute Fate Therapeutics Buy or Sell Advice
The Fate recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Fate Therapeutics. Macroaxis does not own or have any residual interests in Fate Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Fate Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Fate Therapeutics Trading Alerts and Improvement Suggestions
| Fate Therapeutics had very high historical volatility over the last 90 days | |
| Fate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 63.53 M. Net Loss for the year was (160.93 M) with loss before overhead, payroll, taxes, and interest of (224.15 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (132.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: Fate Therapeutics files to sell 3.64M shares for holders |
Fate Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Fate analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Fate analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Fate Therapeutics Returns Distribution Density
The distribution of Fate Therapeutics' historical returns is an attempt to chart the uncertainty of Fate Therapeutics' future price movements. The chart of the probability distribution of Fate Therapeutics daily returns describes the distribution of returns around its average expected value. We use Fate Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Fate Therapeutics returns is essential to provide solid investment advice for Fate Therapeutics.
| Mean Return | 0.35 | Value At Risk | -7.25 | Potential Upside | 9.89 | Standard Deviation | 6.16 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Fate Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Fate Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fate Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fate Therapeutics backward and forwards among themselves. Fate Therapeutics' institutional investor refers to the entity that pools money to purchase Fate Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2023-09-30 | 2 M | Two Sigma Advisers, Llc | 2023-12-31 | 1.9 M | Geode Capital Management, Llc | 2023-12-31 | 1.9 M | State Street Corporation | 2023-12-31 | 1.9 M | Federated Hermes Inc | 2023-12-31 | 1.8 M | Adage Capital Partners Gp Llc | 2023-12-31 | 1.7 M | Two Sigma Investments Llc | 2023-12-31 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.3 M | Vestal Point Capital Lp | 2023-12-31 | 1.3 M | Redmile Group, Llc | 2023-09-30 | 13.1 M | Blackrock Inc | 2023-12-31 | 11.2 M |
Fate Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (90.7M) | 82.5M | (33.8M) | (72.3M) | (19.5M) | (18.5M) | |
| Free Cash Flow | (90.6M) | (44.2M) | (213.6M) | (283.8M) | (138.4M) | (131.5M) | |
| Depreciation | 2.2M | 3.1M | 5.9M | 13.8M | 18.3M | 19.2M | |
| Other Non Cash Items | (7.8M) | 111.4M | (18.1M) | (24.3M) | (44.5M) | (42.3M) | |
| Capital Expenditures | 7.4M | 4.9M | 50.7M | 35.6M | 6.2M | 9.5M | |
| Net Income | (98.1M) | (173.4M) | (212.2M) | (281.7M) | (160.9M) | (152.9M) | |
| End Period Cash Flow | 100.0M | 182.6M | 148.8M | 76.6M | 41.9M | 39.8M | |
| Change To Inventory | (4.3M) | (4.3M) | 1.6M | (5.9M) | (5.3M) | (5.1M) | |
| Change To Netincome | 17.4M | 30.8M | 37.3M | 51.8M | 59.6M | 62.5M | |
| Investments | (150.1M) | (156.1M) | (273.3M) | 166.8M | 120.4M | 126.4M |
Fate Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Fate Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Fate Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Fate stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.09 | |
β | Beta against NYSE Composite | 4.27 | |
σ | Overall volatility | 6.25 | |
Ir | Information ratio | 0.05 |
Fate Therapeutics Volatility Alert
Fate Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Fate Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Fate Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Fate Therapeutics Fundamentals Vs Peers
Comparing Fate Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Fate Therapeutics' direct or indirect competition across all of the common fundamentals between Fate Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Fate Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Fate Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Fate Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Fate Therapeutics to competition |
| Fundamentals | Fate Therapeutics | Peer Average |
| Return On Equity | -0.38 | -0.31 |
| Return On Asset | -0.18 | -0.14 |
| Profit Margin | (2.53) % | (1.27) % |
| Operating Margin | (20.99) % | (5.51) % |
| Current Valuation | 288.52 M | 16.62 B |
| Shares Outstanding | 113.78 M | 571.82 M |
| Shares Owned By Insiders | 1.40 % | 10.09 % |
| Shares Owned By Institutions | 91.81 % | 39.21 % |
| Number Of Shares Shorted | 16.49 M | 4.71 M |
| Price To Earning | (4.35) X | 28.72 X |
| Price To Book | 1.79 X | 9.51 X |
| Price To Sales | 10.33 X | 11.42 X |
| Revenue | 63.53 M | 9.43 B |
| Gross Profit | (224.15 M) | 27.38 B |
| EBITDA | (159.33 M) | 3.9 B |
| Net Income | (160.93 M) | 570.98 M |
| Cash And Equivalents | 568.85 M | 2.7 B |
| Cash Per Share | 5.86 X | 5.01 X |
| Total Debt | 103.54 M | 5.32 B |
| Debt To Equity | 0.19 % | 48.70 % |
| Current Ratio | 6.55 X | 2.16 X |
| Book Value Per Share | 3.73 X | 1.93 K |
| Cash Flow From Operations | (132.26 M) | 971.22 M |
| Short Ratio | 5.95 X | 4.00 X |
| Earnings Per Share | (1.64) X | 3.12 X |
| Target Price | 7.8 | |
| Number Of Employees | 181 | 18.84 K |
| Beta | 1.68 | -0.15 |
| Market Capitalization | 573.47 M | 19.03 B |
| Total Asset | 506.22 M | 29.47 B |
| Retained Earnings | (1.21 B) | 9.33 B |
| Working Capital | 292.45 M | 1.48 B |
| Current Asset | 47.4 M | 9.34 B |
Note: Acquisition by Redmile Group, Llc of 8650 shares of Fate Therapeutics subject to Rule 16b-3 [view details]
Fate Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Fate . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Fate Therapeutics Buy or Sell Advice
When is the right time to buy or sell Fate Therapeutics? Buying financial instruments such as Fate Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 114.8M | 109.3M | 103.5M | 108.7M | Total Assets | 921.5M | 705.6M | 506.2M | 310.1M |
Use Investing Ideas to Build Portfolios
In addition to having Fate Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Healthcare Thematic Idea Now
Healthcare
Companies that provide healthcare goods and services including hospitals, health maintenance organizations, HMOs, or medical aid manufacturers. The Healthcare theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Fate Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.646 | Quarterly Revenue Growth (0.96) | Return On Assets (0.18) | Return On Equity (0.38) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.